Researchers at Rockefeller University in the US have found a new family of antibiotics by conducting a genetic study in a variety of soil samples.

Named malacidins, the calcium-based natural compounds are expected to aid in the treatment of different drug-resistant bacterial infections, reported the BBC.

The researchers said that the lack of new treatments could result in a tenfold increase of mortality rates due to untreatable infections by 2050.

According to the research published in Nature microbiology, the team developed a culture-independent natural products (NP) discovery platform, which employed sequencing, bioinformatic analysis and heterologous expression of biosynthetic gene clusters from DNA obtained in environmental samples.

By using the DNA information of an antibiotic called daptomycin as a reference, the researchers studied the genomes of antibiotics used by microorganisms in more than 2,000 soil samples, reported

“It is impossible to say when, or even if, an early stage antibiotic discovery like the malacidins will proceed to the clinic.”

During the analysis, they discovered malacidins that used calcium to destroy the cell walls of bacteria and in turn addressed the infection caused.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Upon testing in mice induced with methicillin-resistant Staphylococcus (MRSA) that is multidrug-resistant, malacidins were found to have completely eliminated the bacteria.

They also reported that further investigation under laboratory conditions did not reveal any bacterial resistance to malacidins but additional evaluation in clinical trials is required.

Rockefeller University research team member Dr Sean Brady was quoted by the BBC as saying: “It is impossible to say when, or even if, an early stage antibiotic discovery like the malacidins will proceed to the clinic.

“It is a long, arduous road from the initial discovery of an antibiotic to a clinically used entity.”